MyChesCo on MSN6h
FDA Unveils Key Updates on Rare Disease Advances, Food Safety, and Medical InnovationsThe U.S. Food and Drug Administration (FDA) has released a series of announcements covering a wide range of initiatives and ...
Topline results were announced from a phase 3 trial evaluating simufilam, an oral small molecule that targets the filamin A protein, for the treatment of mild to moderate Alzheimer disease (AD).
and ties in with ongoing efforts by the regulator to find and validate digital endpoints that can be used to study diseases and potential new therapies. The competition will be hosted on ...
MedPage Today on MSN9d
FDA Expands Guselkumab Approval to Crohn's DiseaseThe FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...
Incyte's povorcitinib met key Phase 3 trial endpoints in hidradenitis suppurativa, showing significant clinical response and ...
Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer’s disease Alignment with FDA on proposed trial study design, ...
World Effectiveness and Safety of Upadacitinib in Crohn’s Disease: A Multi-Centre Study," published in the March 2025 issue ...
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...
Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback